Intravenous low-dose decitabine versus supportive care in elderly patients with primary myelodysplastic syndrome (MDS) (greater than 10 percent blasts or high-risk cytogenetics), secondary MDS or chronic myelomonocytic leukemia who are not eligible for intensive therapy: an EORTC-German MDS Study Group randomized phase III study.

Trial Profile

Intravenous low-dose decitabine versus supportive care in elderly patients with primary myelodysplastic syndrome (MDS) (greater than 10 percent blasts or high-risk cytogenetics), secondary MDS or chronic myelomonocytic leukemia who are not eligible for intensive therapy: an EORTC-German MDS Study Group randomized phase III study.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Decitabine (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Apr 2011 Final results published in the Journal of Clinical Oncology.
    • 08 Dec 2008 Final results were presented at ASH 2009.
    • 01 Jul 2008 233 patients were enrolled and treated inthis study according to SuperGen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top